Loading...
|
Please use this identifier to cite or link to this item:
http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/96078
|
Title: | Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway |
Authors: | Kuo, Han-Peng;Hsu, Shih-Chung;Ou, Chien-Chih;Li, Jhy-Wei;Tseng, Hsiu-Hsueh;Chuang, Tzu-Chao;Liu, Jah-Yao;Chen, Shih-Jung;Su, Muh-Hwan;Cheng, Yung-Chi;Chou, Wei-Yuan;Kao, Ming-Ching |
Contributors: | 淡江大學化學學系 |
Date: | 2013 |
Issue Date: | 2014-02-20 15:14:00 (UTC+8) |
Publisher: | New York: Hindawi Publishing Corporation |
Abstract: | Ganoderma, also known as Lingzhi or Reishi, has been used for medicinal purposes in Asian countries for centuries. It is a medicinal fungus with a variety of biological properties including immunomodulatory and antitumor activities. In this study, we investigated the molecular mechanisms by which Ganoderma tsugae (GT), one of the most common species of Ganoderma, inhibits the proliferation of HER2-overexpressing cancer cells. Here, we show that a quality assured extract of GT (GTE) inhibited the growth of HER2-overexpressing cancer cells in vitro and in vivo and enhanced the growth-inhibitory effect of antitumor drugs (e.g., taxol and cisplatin) in these cells. We also demonstrate that GTE induced cell cycle arrest by interfering with the HER2/PI3K/Akt signaling pathway. Furthermore, GTE curtailed the expression of the HER2 protein by modulating the transcriptional activity of the HER2 gene and the stability/degradation of the HER2 protein. In conclusion, this study suggests that GTE may be a useful adjuvant therapeutic agent in the treatment of cancer cells that highly express HER2. |
Relation: | Evidence-Based Complementary and Alternative Medicine 2013, 219472(12pages) |
DOI: | 10.1155/2013/219472 |
Appears in Collections: | [化學學系暨研究所] 期刊論文
|
Files in This Item:
File |
Description |
Size | Format | |
index.html | | 0Kb | HTML | 165 | View/Open |
|
All items in 機構典藏 are protected by copyright, with all rights reserved.
|